Ionis Pharmaceuticals Stock News

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)s stock price hit a new 52-week low during trading on Tuesday . The stock traded as low as $27.07 and last traded at $27.21, with a volume of 3057 shares traded. The stock had previously closed at $27.45. Several equities research analysts have commented on IONS shares. Morgan Stanley dropped their []

Even a good year for stocks has its share of high-flyers that have turned into losers — or buying opportunities.

Ionis Pharmaceuticals, Inc. (IONS) with the stream of -5.51% also noticed, India China Jo-Jo Drugstores, Inc. (CJJD) encountered a rapid change of -0.24% in the last hour of Mondays trading The post Traders shouldnt Staggering on this: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) appeared first on Stocks Equity .

Bard Financial Services Inc. bought a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 9,725 shares of the companys stock, valued at approximately $326,000. A number of other hedge funds []

Wall Street brokerages expect Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to post earnings of $0.08 per share for the current quarter, according to Zacks. Six analysts have issued estimates for Ionis Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.07) and the highest estimate coming in at $0.32. Ionis Pharmaceuticals reported earnings per share of []

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) shares, rose in value on Friday, 11/26/21, with the stock price down by -2.39% to the previous days close as strong demand from buyers drove the stock to $29.05. Actively observing the price movement in the last trading, the stock closed the session at $29.76, falling within a range of $28.885 Is Now A Good Time To Invest In Ionis Pharmaceuticals Inc. (NASDAQ: IONS)? Read More »

IFP Advisors Inc grew its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 45.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,720 shares of the companys stock after buying an additional 541 shares during the quarter. IFP Advisors Incs holdings []

Wall Street analysts forecast that Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) will announce sales of $233.97 million for the current quarter, Zacks reports. Six analysts have provided estimates for Ionis Pharmaceuticals earnings. The highest sales estimate is $239.50 million and the lowest is $230.10 million. Ionis Pharmaceuticals posted sales of $290.00 million during the same quarter last []

Ionis Pharmaceuticals, Inc. (IONS) announced that Pfizer (PFE) reported positive results from Phase 2b clinical study of vupanorsen. The post Ionis Reveals Results study of vupanorsen appeared first on Smarter Analyst .

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)s share price reached a new 52-week low on Wednesday . The company traded as low as $28.80 and last traded at $29.14, with a volume of 3221 shares. The stock had previously closed at $30.33. A number of brokerages have recently issued reports on IONS. Needham & Company LLC reduced their []

CARLSBAD, Calif., Nov. 24, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Pfizer has provided an update on the Phase 2b study of vupanorsen, formerly IONIS-ANGPTL3-LRx. Vupanorsen is an investigational antisense therapy being developed for indications

Here are the five best biotech ETFs to invest in right now.

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) have been given an average rating of Hold by the eleven analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. The average []

CARLSBAD, Calif., Nov. 18, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today initiation of OASIS-HAE, the registrational study in the donidalorsen (formerly IONIS-PKK-LRx) Phase 3 clinical program. Donidalorsen is an

Global Berryliosis Treatment Market Synopsis: The finest Berryliosis Treatment Market analysis document enumerates information about the key companies based on their Market position in the present scenario along with data related to the Market sales gathered by the manufacturers along with